Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals (formerly Trimurthi Limited) held an EGM on January 9, 2026, via video conferencing, where both resolutions were passed with 100% votes in favour and zero votes against. Resolution 1 (Special Resolution) approved the issue of equity shares on a preferential basis, securing 10,147,138 votes from 86 shareholders, representing 62.87% of total outstanding shares. Resolution 2 (Ordinary Resolution) confirmed the appointment of Ms. Sridevi Belide (DIN: 10455373) as a Non-Executive Non-Independent Director, also receiving 100% support. Promoters were interested in both resolutions and voted 95.47% of their holding (8,422,733 shares), while public shareholders participated with 23.56% of their holding (1,724,405 shares). The scrutinizer's report by Bharat Khaniwal & Co. validated the voting process and confirmed both resolutions passed with the requisite majority.
The preferential equity share issuance will dilute existing shareholders' stakes and likely result in equity expansion, which existing investors should monitor. The new director appointment strengthens the board, but promoter interest in both resolutions means the preferential allotment may primarily benefit the promoter group.